[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100648856":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":30,"centralContacts":39,"locations":45,"responsibleParty":61,"collaborators":30,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":66,"sex":72,"minAge":73,"maxAge":30,"enrollmentInfo":74,"targetDuration":30,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":84,"overallStatus":47,"whyStopped":30,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"Shanghai Public Health Clinical Center","OTHER_GOV",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Oral ART","OTHER","Participants will receive standard oral antiretroviral therapy throughout lymphoma treatment.",[13],"Drug: Oral Antiretroviral Therapy",{"label":15,"type":10,"description":16,"interventionNames":17},"Oral ART Plus Albuvirtide","Participants with viremia who agree to receive long-acting therapy will receive oral ART combined with intravenous albuvirtide.",[13,18],"Drug: albuvirtide",{"label":20,"type":10,"description":21,"interventionNames":22},"Long-Acting Cabotegravir\u002FRilpivirine","Eligible participants will receive long-acting intramuscular cabotegravir and rilpivirine according to the approved dosing schedule.",[23],"Drug: Cabotegravir\u002FRilpivirine",[25,31,35],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","Oral Antiretroviral Therapy","Bictegravir\u002FEmtricitabine\u002FTenofovir Alafenamide (BIC\u002FFTC\u002FTAF)\n\nor\n\nCurrent Oral ART Regimen at lymphoma diagnosis",[9,15],null,{"type":26,"name":32,"description":33,"armGroupLabels":34,"otherNames":30},"albuvirtide","Albuvirtide 640 mg intravenously every 4 weeks for five doses.",[15],{"type":26,"name":36,"description":37,"armGroupLabels":38,"otherNames":30},"Cabotegravir\u002FRilpivirine","long-acting intramuscular cabotegravir and rilpivirine according to the approved dosing schedule.",[20],[40],{"name":41,"role":42,"phone":43,"phoneExt":30,"email":44},"Zhenyan Wang","CONTACT","+86021-37990333-3222","wangzhenyan@shaphc.org",[46],{"facility":5,"status":47,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"RECRUITING","Shanghai","Shanghai Municipality","201508","China","CN",{"type":54,"coordinates":55},"Point",[56,57],121.45806,31.22222,{"lat":57,"lon":56},[60],{"name":41,"role":42,"phone":43,"phoneExt":30,"email":44},{"type":62,"investigatorFullName":41,"investigatorTitle":63,"investigatorAffiliation":5,"oldNameTitle":30,"oldOrganization":30},"PRINCIPAL_INVESTIGATOR","Associate Chief Physician","100648856","optimization-of-antiretroviral-therapy-in-patients-with-aids-related-lymphoma-100648856",false,"NCT07727642","Optimization of Antiretroviral Therapy in Patients With AIDS-Related Lymphoma","Optimization of Antiretroviral Therapy in Patients With AIDS-Related Lymphoma During Anti-Lymphoma Treatment: A Multicenter Prospective Non-Randomized Controlled Study","OPT-ARL","Inclusion Criteria:\n\n\\- Age ≥18 years. Confirmed HIV infection. Histologically confirmed AIDS-related lymphoma. Receiving anti-lymphoma treatment. Able and willing to provide written informed consent.\n\nExclusion Criteria:\n\n\\- Expected survival less than 6 months. Severe concomitant malignancy or uncontrolled comorbidity. Refusal to receive antiretroviral therapy or lymphoma treatment. Contraindications to study medications. Inability to complete scheduled follow-up. Any condition considered unsuitable by the investigator.","ALL","18 Years",{"count":75,"type":76},60,"ESTIMATED","INTERVENTIONAL",[79],"NA","The goal of this clinical trial is to evaluate the efficacy and safety of different antiretroviral therapy (ART) strategies in adults with AIDS-related lymphoma (ARL) receiving anti-lymphoma treatment. The main questions it aims to answer are:\n\nDoes long-acting injectable ART, including albuvirtide (ABT) or long-acting cabotegravir\u002Frilpivirine (CAB\u002FRPV), improve virological suppression compared with oral ART during anti-lymphoma treatment? Do different ART strategies differ in immune recovery, virological failure, low-level viremia, and safety in patients with ARL?\n\nResearchers will compare three treatment strategies-oral ART alone, oral ART plus long-acting albuvirtide (ABT), and long-acting cabotegravir\u002Frilpivirine (CAB\u002FRPV)-to determine whether long-acting injectable ART provides better virological control and comparable safety during lymphoma treatment.\n\nParticipants will:\n\nReceive one of three ART strategies according to their clinical condition and treatment preference while receiving standard anti-lymphoma therapy.\n\nAttend scheduled study visits at baseline and Weeks 4, 8, 12, 24, 36, and 48. Undergo plasma HIV-1 RNA testing, CD4+ T-cell count measurement, laboratory assessments, and safety evaluations throughout the 48-week follow-up period.\n\nBe monitored for virological suppression, immune recovery, adverse events, and lymphoma-related clinical outcomes.",[82,83],"AIDS-related Lymphoma","HIV Infection",[85,86,87,88,89,90,91,92],"HIV","AIDS-Related Lymphoma","Antiretroviral Therapy","Albuvirtide","Cabotegravir","Rilpivirine","Long-Acting Injectable ART","Virological Suppression","2026-07-22",{"date":95,"type":96},"2026-07-27","ACTUAL",{"date":98,"type":96},"2026-05-26",{"date":100,"type":76},"2028-07",{"name":5,"class":6},1]